Sony Biotechnology Inc. Sony Biotechnology Inc.cart
About Us Products What's New Library News Calendar Contact Us Place Order
Safety Data Sheet (SDS) FITC Anti-mouse Ly-49C/F/I/H Antibody     Product Data Sheet (PDF)    
FITC Anti-mouse Ly-49C/F/I/H Antibody
1141025 50 µg $85.00       
Clone: 14B11
Isotype: Syrian Hamster IgG
Reactivity: Mouse
Immunogen: IL-2-activated killer cells (LAK) from C57BL/6 mice
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application:

FC - Quality tested

Application Notes:

Additional reported applications (for the relevant formats) include: induction of redirected lysis1, and blocking2 of the binding of H-2d lymphoblasts to transfectants expressing Ly-49C, Ly-49F, and Ly-49I.

This product may be used for research purposes only. It is not licensed for resale and may only be used by the buyer. This product may not be used and is not licensed for clinical assays, where the results of such assays are provided as a diagnostic service. If a diagnostic or therapeutic use is anticipated, then a license must be requested for the University of California. The availability of such diagnostic and therapeutic use license(s) cannot be guaranteed from the University of California. 

Recommended Usage:

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application References:

1. Corral L, et al. 1999. Hybridoma 18:359.
2. Hanke T, et al. 1999. Immunity 11:67.
3. Cao D, et al. 2009. Transpl Immunol. 20:243. PubMed

C57BL/6 mouse splenocytes stained with

C57BL/6 mouse splenocytes stained with 14B11 FITC



Description:

The 14B11 antibody reacts with a common epitope of Ly-49C/F/I/H family members also known as Ly-49 inhibitory receptors C, F, and I and activating receptor H. It does not react with other Ly-49 members (i.e., Ly-49A, B, D, and G). Ly-49 is a type-II transmembrane, disulfide-linked homodimer with C-type lectin extracellular domains that binds to MHC class I. Ly-49C/F/I/H is expressed on a subset of NK cells, NK-T cells and some CD8+ cells. Ly-49C/F/I, like other members of this family, inhibits NK cell activation through the recognition and interaction of certain MHC class I haplotypes on potential target cells. Ly-49C, Ly-49F, and Ly-49I contain an ITIM motif in their cytoplasmic tails, while Ly-49H lacks ITIM. Ly-49H is encoded by the Cmv1r gene, which promotes resistance to infection by mouse cytomegalovirus (CMV). BALB/c mice are reported to lack the Ly-49H and Ly-49I receptors. The 14B11 antibody, when bound to NK cells, is capable of inducing redirected cell lysis and blocking NK cell effector function.


This product may be used for research purposes only. It is not licensed for resale and may only be used by the buyer. This product may not be used and is not licensed for clinical assays, where the results of such assays are provided as a diagnostic service. If a diagnostic or therapeutic use is anticipated, then a license must be requested for the University of California. The availability of such diagnostic and therapeutic use license(s) cannot be guaranteed from the University of California. 

Other Names: Ly-49 inhibitory receptors C, F and I and the activating receptor H
Structure: Ly-49 family, 110 kD
Distribution: NK and NK-T cells, some CD8+ T cells
Function: NK cell activation or inhibition
Ligand Receptor: MHC Class I Molecules
Antigen References:

1. Ryan JC, et al. 1997. Immunol. Rev. 155:79.
2. Mason LH, et al. 1997. J. Immunol. 159:4187.
3. Lanier LL. 1998. Ann. Rev. Immunol. 16:359.
4. Yokoyama W, et al. 1993. Ann. Rev. Immunol. 11:613.